SK Life Science to Present New Epilepsy Data at American Academy of Neurology Meeting
SK Life Science, Inc. is set to present multiple posters at the American Academy of Neurology (AAN) Annual Meeting in Chicago, Illinois, from April 18-22, 2026. The presentations will focus on clinical and real-world evidence related to cenobamate, an antiseizure medication marketed under the brand name XCOPRI® in the U.S. The company will also share insights from the 'Hope, Hesitancy, and Hard Truths' survey, which examines communication between epilepsy patients and healthcare providers. The survey aims to identify communication gaps that may impact treatment decisions and patient outcomes. 
